A citation-based method for searching scientific literature

Ningning Yan, Sanxing Guo, Huixian Zhang, Ziheng Zhang, Shujing Shen, Xingya Li. Front Oncol 2022
Times Cited: 5







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical considerations for the design of PROTACs in cancer.
Cristina Nieto-Jiménez, Esther Cabañas Morafraile, Carlos Alonso-Moreno, Alberto Ocaña. Mol Cancer 2022
11
40

PROTAC targeted protein degraders: the past is prologue.
Miklós Békés, David R Langley, Craig M Crews. Nat Rev Drug Discov 2022
121
40

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
476
40

Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.
Ding Li, Zhenguo Song, Bingqi Dong, Wenping Song, Cheng Cheng, Yongna Zhang, Wenzhou Zhang. J Clin Pharm Ther 2022
3
33


Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.
Yihui Song, Shu Wang, Min Zhao, Xinyu Yang, Bin Yu. J Med Chem 2022
13
20

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
Sumitra Thongprasert, Emma Duffield, Nagahiro Saijo, Yi-Long Wu, James Chih-Hsin Yang, Da-Tong Chu, Meilin Liao, Yuh-Min Chen, Han-Pin Kuo, Shunichi Negoro,[...]. J Thorac Oncol 2011
101
20

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Alissa J Cooper, Lecia V Sequist, Jessica J Lin. Nat Rev Clin Oncol 2022
10
20

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yunfang Yu, Dongqiang Zeng, Qiyun Ou, Shengbo Liu, Anlin Li, Yongjian Chen, Dagui Lin, Quanlong Gao, Haiyu Zhou, Wangjun Liao,[...]. JAMA Netw Open 2019
115
20

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
Isamu Okamoto, Satoshi Morita, Naoki Tashiro, Fumio Imamura, Akira Inoue, Takashi Seto, Nobuyuki Yamamoto, Yuichiro Ohe, Kazuhiko Nakagawa, Masahiro Fukuoka. Lung Cancer 2018
53
20


Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer.
Qian Zhao, Zhongtang Wang, Wei Huang, Qiang Wang, Shuzeng Yu, Tao Zhou, Dan Han, Zhenying Wu, Heyi Gong, Hongfu Sun,[...]. Oncotarget 2016
5
20

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Roy S Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, Alain Vergnenegre, Carlos H Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andric, Sarayut Geater,[...]. N Engl J Med 2020
458
20

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
Caicun Zhou, Suresh S Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J Riely, Tarek Mekhail, Danny Nguyen, Maria R Garcia Campelo, Enriqueta Felip,[...]. JAMA Oncol 2021
56
20


Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
20

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
665
20


Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Julien Mazieres, Dariusz Kowalski, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Konstantin Laktionov, Barbara Hermes, Irfan Cicin, Jerónimo Rodríguez-Cid,[...]. J Clin Oncol 2020
36
20

Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Shinya Sakata, Kohei Otsubo, Hisako Yoshida, Kentaro Ito, Atsushi Nakamura, Shunsuke Teraoka, Naohisa Matsumoto, Yoshimasa Shiraishi, Koji Haratani, Motohiro Tamiya,[...]. Cancer Sci 2022
8
20

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
20

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
20

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
20

Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.
Kazuhisa Nakashima, Yuichi Ozawa, Haruko Daga, Hisao Imai, Motohiro Tamiya, Takaaki Tokito, Takahisa Kawamura, Hiroaki Akamatsu, Yuko Tsuboguchi, Toshiaki Takahashi,[...]. Invest New Drugs 2020
7
20

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, Timothy J Price, Gerald S Falchook, Jürgen Wolf, Antoine Italiano, Martin Schuler, Hossein Borghaei, Fabrice Barlesi,[...]. N Engl J Med 2021
295
20

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
287
20

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp,[...]. N Engl J Med 2018
20

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
20


Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
261
20

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.
Lee M Ellis, David S Bernstein, Emile E Voest, Jordan D Berlin, Daniel Sargent, Patricia Cortazar, Elizabeth Garrett-Mayer, Roy S Herbst, Rogerio C Lilenbaum, Camelia Sima,[...]. J Clin Oncol 2014
293
20

Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Yoshihiko Segawa, Katsuyuki Kiura, Nagio Takigawa, Haruhito Kamei, Shingo Harita, Shunkichi Hiraki, Yoichi Watanabe, Keisuke Sugimoto, Takuo Shibayama, Toshiro Yonei,[...]. J Clin Oncol 2010
171
20

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Hossein Borghaei, Scott Gettinger, Everett E Vokes, Laura Q M Chow, Marco Angelo Burgio, Javier de Castro Carpeno, Adam Pluzanski, Oscar Arrieta, Osvaldo Arén Frontera, Rita Chiari,[...]. J Clin Oncol 2021
140
20

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
20

Mechanisms of Resistance to KRASG12C-Targeted Therapy.
Neal S Akhave, Amadeo B Biter, David S Hong. Cancer Discov 2021
20
20

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer.
Lingzhi Hong, Jianjun Zhang, John V Heymach, Xiuning Le. Ther Adv Med Oncol 2021
18
20

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H Lee, Maike de Wit,[...]. N Engl J Med 2017
20

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Alan Sandler, Robert Gray, Michael C Perry, Julie Brahmer, Joan H Schiller, Afshin Dowlati, Rogerio Lilenbaum, David H Johnson. N Engl J Med 2006
20

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. J Clin Oncol 2021
152
20

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.
Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, Keita Kudo, Kimio Yonesaka, Ryoji Kato, Hiroyasu Kaneda, Yoshikazu Hasegawa, Kaoru Tanaka, Masayuki Takeda,[...]. JAMA Oncol 2018
535
20

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi,[...]. J Clin Oncol 2018
165
20

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Keunchil Park, Eng-Huat Tan, Ken O'Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih-Hsin Yang, Ki Hyeong Lee, Shun Lu,[...]. Lancet Oncol 2016
712
20

Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
Ulla von Verschuer, Roland Schnell, Hans Werner Tessen, Jochen Eggert, Adrian Binninger, Lisa Spring, Martina Jänicke, Norbert Marschner. Lung Cancer 2017
16
20

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
253
20

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, Tony Mok, Johannes Noe, Malgorzata Nowicka, Shirish M Gadgeel, Parneet Cheema, Nick Pavlakis, Filippo de Marinis,[...]. J Thorac Oncol 2019
209
20

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rolf Linke, Rafael Rosell, Jesus Corral,[...]. Lancet Oncol 2017
619
20

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
20

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
20

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
Christian Rolfo, Philip Mack, Giorgio V Scagliotti, Charu Aggarwal, Maria E Arcila, Fabrice Barlesi, Trever Bivona, Maximilian Diehn, Caroline Dive, Rafal Dziadziuszko,[...]. J Thorac Oncol 2021
98
20

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
272
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.